While U.S. President Donald Trump’s country-by-country reciprocal and newly negotiated tariffs go into effect today, a separate, global biopharma sector tariff of, possibly, 200% continues to loom over the sector. For many stakeholders, a biopharma sector tariff of even 25%, as first proposed by Trump, would be a disaster in the making, especially when combined with the pressures of Medicare price negotiations and the president’s escalation of most-favored-nation pricing.
The Senate Appropriations Committee met July 31 to markup legislation that would fund the Department of Health and Human Services – including an additional $400 million for the National Institutes of Health. The increase in NIH funding repudiates the Trump administration’s efforts to drastically cut those appropriations, which is an outcome marking a clear win for companies in the life sciences.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bioaffinity Technologies, Etiometry, Evvy, Guardant Health, Omron Healthcare, Preludedx.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aptitude Medical, Arkstone Medical, Paragon Genomics, Genecast, Natera, Newgenivf, Pavmed, Royal Philips, Vivex, Viz.ai.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alafair Biosciences, Evoendo, Setpoint Medical.
RSS
